Metabonomic profiles delineate the effect of traditional Chinese medicine Sini decoction on myocardial infarction in rats

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tan, Guangguo ^a,b   Liao, Wenting ^a,b   Dong, Xin ^a   Yang, Genjing ^a   Zhu, Zhenyu ^a,b   Li, Wuhong ^a,b   Chai, Yifeng ^a,b   Lou, Ziyang ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHANGHAI KEY LABORATORY FOR PHARMACEUTICAL METABOLITE RESEARCH   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HERBACEOUS AGENT; SINI TANG;

AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CITRIC ACID CYCLE; CONTROLLED STUDY; DRUG MECHANISM; ELECTROCARDIOGRAPHY; ENERGY METABOLISM; GLYCOLYSIS; HEART INFARCTION; HISTOPATHOLOGY; MALE; MASS SPECTROMETRY; METABOLOMICS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; PURINE METABOLISM; PYRIMIDINE METABOLISM; RAT; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; ANIMAL; CHINESE MEDICINE; DISEASE MODEL; DRUG EFFECT; HEART MUSCLE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METABOLISM; METABOLOME; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; URINE;

RATTUS;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISEASE MODELS, ANIMAL; DRUGS, CHINESE HERBAL; ENERGY METABOLISM; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MASS SPECTROMETRY; MEDICINE, CHINESE TRADITIONAL; METABOLOME; METABOLOMICS; MYOCARDIAL INFARCTION; MYOCARDIUM; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84859510098     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034157     Document Type: Article

References (54)

1. Weir RA, McMurray JJ, (2006) Epidemiology of heart failure and left ventricular dysfunction after acute myocardial infarction. Curr Heart Fail Rep 3: 175-180.
2. Torabi A, Cleland JG, Khan NK, Loh PH, Clark AL, et al. (2008) The timing of development and subsequent clinical course of heart failure after a myocardial infarction. Eur Heart J 29: 859-870.
3. Efferth T, Li PC, Konkimalla VS, Kaina B, (2007) From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 13: 353-361.
4. Wen Z, Wang Z, Wang S, Ravula R, Yang L, et al. (2011) Discovery of molecular mechanisms of traditional Chinese medicinal formula Si-Wu-Tang using gene expression microarray and connectivity map. PLoS One 6: e18278.
5. Jin M, Qin J, Wu W, (2003) Clinical study on "sini" decoction in treating stenocardia for coronary heart disease. Zhong Yao Cai 26: 71-73.
6. Wu W, Su J, Lin S, (1999) Clinical study on therapeutic mechanism of Sini Decoction in treating post-percutaneous transluminal coronary angioplasty ischemia-reperfusion injury in terms of syndrome typing of TCM. Zhongguo Zhong Xi Yi Jie He Za Zhi 19: 23-26.
7. Zhao MQ, Qian J, Wu WK, (2003) Observation of Sini decoction on myocardial apoptosis induced by ischemia/reperfusion and its mechanism. Zhongguo Zhong Xi Yi Jie He Za Zhi 23: 1-4.
8. Tan G, Zhu Z, Jing J, Lv L, Lou Z, et al. (2011) Characterization of constituents in Sini decoction and rat plasma by high-performance liquid chromatography with diode array detection coupled to time-of-flight mass spectrometry. Biomed Chromatogr 25: 913-924.
9. Nicholson JK, Lindon JC, Holmes E, (1999) 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 29: 1181-1189.
10. Fiehn O, (2002) Metabolomics-the link between genotypes and phenotypes. Plant Mol Biol 48: 155-171.
11. Wang M, Lamers RJ, Korthout HA, van Nesselrooij JH, Witkamp RF, et al. (2005) Metabolomics in the context of systems biology: bridging traditional Chinese medicine and molecular pharmacology. Phytother Res 19: 173-182.
12. Verpoorte R, Choi YH, Kim HK, (2005) Ethnopharmacology and systems biology: a perfect holistic match. J Ethnopharmacol 100: 53-56.
13. Giovane A, Balestrieri A, Napoli C, (2008) New insights into cardiovascular and lipid metabolomics. J Cell Biochem 105: 648-654.
14. Lindon JC, Holmes E, Nicholson JK, (2006) Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res 23: 1075-1088.
15. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
16. Janis MT, Laaksonen R, Oresic M, (2008) Metabolomic strategies to identify tissue-specific effects of cardiovascular drugs. Expert Opin Drug Metab Toxicol 4: 665-680.
17. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, et al. (2007) Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2: 2692-2703.
18. Han J, Datla R, Chan S, Borchers CH, (2009) Mass spectrometry-based technologies for high-throughput metabolomics. Bioanalysis 1: 1665-1684.
19. Theodoridis G, Gika HG, Wilson ID, (2008) LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics. TrAC Trends Anal Chem 27: 251-260.
20. Hodson MP, Dear GJ, Roberts AD, Haylock CL, Ball RJ, et al. (2007) A gender-specific discriminator in Sprague-Dawley rat urine: the deployment of a metabolic profiling strategy for biomarker discovery and identification. Anal Biochem 362: 182-192.
21. Williams RE, Lenz EM, Evans JA, Wilson ID, Granger JH, et al. (2005) A combined (1)H NMR and HPLC-MS-based metabonomic study of urine from obese (fa/fa) Zucker and normal Wistar-derived rats. J Pharm Biomed Anal 38: 465-471.
22. Williams RE, Lenz EM, Lowden JS, Rantalainen M, Wilson ID, (2005) The metabonomics of aging and development in the rat: an investigation into the effect of age on the profile of endogenous metabolites in the urine of male rats using 1H NMR and HPLC-TOF MS. Mol Biosyst 1: 166-175.
23. Lenz EM, Bright J, Knight R, Westwood FR, Davies D, et al. (2005) Metabonomics with 1H-NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 10: 173-187.
24. Holmes E, Foxall PJ, Spraul M, Farrant RD, Nicholson JK, et al. (1997) 750 MHz 1H NMR spectroscopy characterisation of the complex metabolic pattern of urine from patients with inborn errors of metabolism: 2-hydroxyglutaric aciduria and maple syrup urine disease. J Pharm Biomed Anal 15: 1647-1659.
25. Pechlivanis A, Kostidis S, Saraslanidis P, Petridou A, Tsalis G, et al. (2010) (1)H NMR-based metabonomic investigation of the effect of two different exercise sessions on the metabolic fingerprint of human urine. J Proteome Res 9: 6405-6416.
26. Trygg J, Holmes E, Lundstedt T, (2007) Chemometrics in metabonomics. J Proteome Res 6: 469-479.
27. Zou H, Hastie T, (2005) Regularization and variable selection via the elastic net. J R Statist Soc B 67: 301-320.
28. Sangster T, Major H, Plumb R, Wilson AJ, Wilson ID, (2006) A pragmatic and readily implemented quality control strategy for HPLC-MS and GC-MS-based metabonomic analysis. Analyst 131: 1075-1078.
29. Gika HG, Theodoridis GA, Wingate JE, Wilson ID, (2007) Within-day reproducibility of an HPLC-MS-based method for metabonomic analysis: application to human urine. J Proteome Res 6: 3291-3303.
30. Singhuber J, Zhu M, Prinz S, Kopp B, (2009) Aconitum in traditional Chinese medicine: a valuable drug or an unpredictable risk? J Ethnopharmacol 126: 18-30.
31. Maier LS, Schwan C, Schillinger W, Minami K, Schutt U, et al. (2000) Gingerol, isoproterenol and ouabain normalize impaired post-rest behavior but not force-frequency relation in failing human myocardium. Cardiovasc Res 45: 913-924.
32. Kobayashi M, Ishida Y, Shoji N, Ohizumi Y, (1988) Cardiotonic action of [8]-gingerol, an activator of the Ca++-pumping adenosine triphosphatase of sarcoplasmic reticulum, in guinea pig atrial muscle. J Pharmacol Exp Ther 246: 667-673.
33. Asl MN, Hosseinzadeh H, (2008) Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res 22: 709-724.
34. Yu SM, Kuo SC, (1995) Vasorelaxant effect of isoliquiritigenin, a novel soluble guanylate cyclase activator, in rat aorta. Br J Pharmacol 114: 1587-1594.
35. Somjen D, Knoll E, Vaya J, Stern N, Tamir S, (2004) Estrogen-like activity of licorice root constituents: glabridin and glabrene, in vascular tissues in vitro and in vivo. J Steroid Biochem Mol Biol 91: 147-155.
36. Mendes-Silva W, Assafim M, Ruta B, Monteiro RQ, Guimaraes JA, et al. (2003) Antithrombotic effect of Glycyrrhizin, a plant-derived thrombin inhibitor. Thromb Res 112: 93-98.
37. Butt MS, Sultan MT, (2011) Ginger and its health claims: molecular aspects. Crit Rev Food Sci Nutr 51: 383-393.
38. Neubauer S, (2007) The failing heart-an engine out of fuel. N Engl J Med 356: 1140-1151.
39. Stanley WC, Recchia FA, Lopaschuk GD, (2005) Myocardial substrate metabolism in the normal and failing heart. Physiol Rev 85: 1093-1129.
40. Stanley WC, Sabbah HN, (2005) Metabolic therapy for ischemic heart disease: the rationale for inhibition of fatty acid oxidation. Heart Fail Rev 10: 275-279.
41. Guth BD, Wisneski JA, Neese RA, White FC, Heusch G, et al. (1990) Myocardial lactate release during ischemia in swine. Relation to regional blood flow. Circulation 81: 1948-1958.
42. Dyck JR, Cheng JF, Stanley WC, Barr R, Chandler MP, et al. (2004) Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94: e78-84.
43. Sabatine MS, Liu E, Morrow DA, Heller E, McCarroll R, et al. (2005) Metabolomic identification of novel biomarkers of myocardial ischemia. Circulation 112: 3868-3875.
44. McNulty PH, Jacob R, Deckelbaum LI, Young LH, (2000) Effect of hyperinsulinemia on myocardial amino acid uptake in patients with coronary artery disease. Metabolism 49: 1365-1369.
45. Tuunanen H, Knuuti J, (2011) Metabolic remodelling in human heart failure. Cardiovasc Res 90: 251-257.
46. Yaoita H, Fischman AJ, Strauss HW, Saito T, Sato E, et al. (1993) Uridine: a marker of myocardial viability after coronary occlusion and reperfusion. Int J Card Imaging 9: 273-280.
47. Bauer JA, Moffatt-Bruce SD, Elton TS, Feldman D, (2008) Purine metabolism in heart failure: oxidant biology and therapeutic indications. Congest Heart Fail 14: 283-284.
48. Lv Y, Liu X, Yan S, Liang X, Yang Y, et al. (2010) Metabolomic study of myocardial ischemia and intervention effects of Compound Danshen Tablets in rats using ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal 52: 129-135.
49. Gordon A, Hultman E, Kaijser L, Kristjansson S, Rolf CJ, et al. (1995) Creatine supplementation in chronic heart failure increases skeletal muscle creatine phosphate and muscle performance. Cardiovasc Res 30: 413-418.
50. Yamaguchi F, Sanbe A, Takeo S, (1997) Cardiac sarcoplasmic reticular function in rats with chronic heart failure following myocardial infarction. J Mol Cell Cardiol 29: 753-763.
51. Nielsen S, Terris J, Andersen D, Ecelbarger C, Frokiaer J, et al. (1997) Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct. Proc Natl Acad Sci U S A 94: 5450-5455.
52. Roepke TK, King EC, Reyna-Neyra A, Paroder M, Purtell K, et al. (2009) Kcne2 deletion uncovers its crucial role in thyroid hormone biosynthesis. Nat Med 15: 1186-1194.
53. Smith CA, Want EJ, O'Maille G, Abagyan R, Siuzdak G, (2006) XCMS: processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification. Anal Chem 78: 779-787.
54. Bijlsma S, Bobeldijk I, Verheij ER, Ramaker R, Kochhar S, et al. (2006) Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. Anal Chem 78: 567-574.